A nice little announcement tomorrow morning that doesn't cause the SP to go lower would be nice !LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that CEO, Shaun Bagai, will present at theROTH MKM Healthcare Opportunities Conferencein New York on October 12, 2023.
Moderated by Scott Henry, Managing Director, Senior Research Analyst & Head of Pharmaceuticals Research at ROTH Capital Partners, LLC, will conduct a fireside chat with Mr. Bagai, who will discuss recent Company milestones, including the research collaboration with Imugene (ASX: IMU),and highlights from RenovoRx’s open label pivotal Phase III TIGeR- PaC study.
Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform.
TAMP is expected to enable localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver tumors.
Los Altos, CA and Sydney, Australia, July 20, 2023– RenovoRx, Inc. (“RenovoRx”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd(“Imugene”) (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
“We believe the synergy between RenovoRx’s trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients,” said Leslie Chong, Managing Director & Chief Executive Officer of Imugene.
“Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally advanced disease to treating metastatic disease with immunotherapy,” said Shaun Bagai, Chief Executive Officer, RenovoRx. “We look forward to combining our proprietary TAMP platform with Imugene’s CF33 oncolytic virus with the goal of optimizing clinical benefits for patients.”
As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform. The ability to treat difficult-to-access tumors, such as pancreatic and liver cancers, by delivering CF33 trans-arterially may be valuable to cancer patients compared to traditional administration methods where dense fibrous tissue and lack of blood vessels supplying the tumors have been shown to limit therapy uptake.
The TAMP platform is designed to ensure precise therapeutic delivery to a target tissue. In a study presented at the Society of Interventional Radiology 2019 Annual Meeting, the proprietary platform demonstrated a 100-fold (two orders of magnitude) increase in local tissue concentration with TAMP compared to conventional IV delivery as well as advantages compared to off-the-shelf intra-arterial (IA) delivery. TAMP’s unique approach to treatment delivery offers the potential to increase an oncology therapy’s efficacy, improve safety, and widen its therapeutic window by focusing its distribution uniformly in target tissue.
RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards– Life Sciences Edition 2020 for its TAMP therapy platform technology.
| 1.17 |  -0.02 / -1.74%Today’s Change | 0.91 TODAY|||52-Week Range 5.75 | -50.21% Year-to-Date |
|---|
Stock Price Forecast
The 2 analysts offering 12-month price forecasts for RenovoRx Inc have a median target of 8.50, with a high estimate of 13.00 and a low estimate of 4.00. The median estimate represents a+626.50%increase from the last price of 1.17.
Analyst Recommendations
Stock Price Forecast
(20min delay)